NIDA CTN-0152: Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: a Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

开始日期2025-09-16

申办/合作机构

University of Cincinnati (Ohio)

[+1]

ACTRN12624001278527 / Not yet recruiting临床3期

Effect of tirzepatide on asthma control in obese asthmatics aged 16 years and over: A phase III randomised double blinded placebo control trial

开始日期2025-06-02

申办/合作机构

The University of Queensland

NCT06657209 / Not yet recruiting临床4期IIT

Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide

This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD) and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.

开始日期2024-12-15

申办/合作机构

Stanford University

100 项与替尔泊肽相关的临床结果

登录后查看更多信息

100 项与替尔泊肽相关的转化医学

登录后查看更多信息

100 项与替尔泊肽相关的专利（医药）

登录后查看更多信息

558

项与替尔泊肽相关的文献（医药）

2025-01-01·Journal of Affective Disorders

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)

Article

作者: Mansur, Rodrigo B ; McIntyre, Roger S ; Teopiz, Kayla M ; Rosenblat, Joshua D. ; Rhee, Taeho Greg ; Cao, Bing ; Le, Gia Han ; Wong, Sabrina ; Kwan, Angela T H ; Teopiz, Kayla ; Kwan, Angela T.H. ; Ho, Roger ; Mansur, Rodrigo B. ; McIntyre, Roger S. ; Rosenblat, Joshua D

INTRODUCTIONReports of suicidality associated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been reported to the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). We previously reported an increased reporting odds ratio (ROR) of some measures of suicidality with semaglutide and liraglutide using the FDA Adverse Event Reporting System (FAERS). Notwithstanding the increased ROR, causality between GLP-1 RAs exposure and any aspect of suicidality is not established.RESEARCH DESIGN AND METHODSThe analysis herein aims to extend a previous analysis of the FAERS by evaluating the ROR for suicidality reported to the World Health Organization (WHO) Pharmacovigilance Database (VigiBase). We aimed to characterize the ROR of suicidality associated with GLP-1 RAs, as extrapolated from spontaneous reports. As per our previous report, the ROR was considered significant when the lower limit of the 95 % confidence (CI) was >1.0.RESULTSWe searched VigiBase reports from inception to January 2024. The RORs for suicidal ideation were significantly increased for semaglutide (5.82), liraglutide (4.03) and tirzepatide (2.25). For "depression/suicidal", the ROR was significantly increased for semaglutide (14.74) and liraglutide (5.86); and for suicidal behaviour, the ROR was significantly increased for semaglutide (6.52) and liraglutide (3.90). However, for suicide attempts, the ROR was significantly decreased for semaglutide (0.11), dulaglutide (0.075), exenatide (0.047) and liraglutide (0.15). For completed suicide, the ROR was also significantly decreased for semaglutide (0.01), dulaglutide (0.003), exenatide (0.002) and liraglutide (0.008).CONCLUSIONUnlike our previous report with FAERS, a mixed pattern of ROR emerged in the WHO VigiBase with respect to suicidality and exposure to select GLP-RAs. Causation between GLP-1 RA exposure and suicidality (either increased or decreased) cannot be ascertained from ROR data.

2024-12-31·Journal of Medical Economics

Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia

Article

作者: Alzubaidi, Lamya M ; Al-Harbi, Ibtisam ; Akhtar, Omar ; Hassan, Mohamed ; Omaer, Abubker ; Al-Harbi, Bandar ; Almodaimegh, Hind S ; Al-Omar, Hussain A

BACKGROUND AND OBJECTIVESThis study presents a budget impact analysis (BIA) conducted in Saudi Arabia, evaluating the cost implications of adopting semaglutide, tirzepatide, or dulaglutide in the management of type 2 diabetes mellitus (T2DM) patients. The analysis aims to assess the individual budgetary impact of these treatment options on healthcare budgets and provide insights for decision-makers.METHODSA prevalence-based BIA was developed using real-world and clinical trials data. The model considered disease epidemiology, medication prices, diabetes management expenses, cardiovascular (CV) complications costs, and weight reduction savings over a 5-year time horizon. One-way and probabilistic sensitivity analyses (OWSA, PSA) were performed to assess the robustness of the results.RESULTSOver a 5-year period, the cumulative budget impact for semaglutide, tirzepatide, and dulaglutide were 85,923,089 USD, 169,790,195 USD, and 94,558,356 USD, respectively. Hypothetical scenarios considering price parity between semaglutide and tirzepatide are associated with financial impacts of 85,923,091 USD and 86,475,335 USD, respectively. In the public sector, semaglutide showed the lowest incidence of 3-point major adverse CV events (3P-MACE), with tirzepatide leading in weight loss and HbA1c reduction, and dulaglutide presenting the highest 3P-MACE rates and least improvements in HbA1c and weight. A breakeven analysis suggested that tirzepatide's list price would need to be $199.91 lower than its current list price to achieve budget impact parity with semaglutide based on currently available evidence. Results from the OWSA suggested that risk reductions for CV events were key drivers of budget impact. PSA results were confirmatory of base-case analyses.CONCLUSIONSCV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.

2024-12-01·Diabetes, Obesity and Metabolism

Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps

Review

作者: Ravussin, Eric ; Heymsfield, Steven B. ; Dubin, Robert L. ; Greenway, Frank L.

AbstractExcess adiposity is at the root of type 2 diabetes (T2D). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as first‐line treatments for T2D based on significant weight loss results. The composition of weight loss using most diets consists of <25% fat‐free mass (FFM) loss, with the remainder from fat stores. Higher amounts of weight loss (achieved with metabolic bariatric surgery) result in greater reductions in FFM. Our aim was to assess the impact that GLP‐1RA‐based treatments have on FFM. We analysed studies that reported changes in FFM with the following agents: exenatide, liraglutide, semaglutide, and the dual incretin receptor agonist tirzepatide. We performed an analysis of various weight loss interventions to provide a reference for expected changes in FFM. We evaluated studies using dual‐energy X‐ray absorptiometry (DXA) for measuring FFM (a crude surrogate for skeletal muscle). In evaluating the composition of weight loss, the percentage lost as fat‐free mass (%FFML) was equal to ΔFFM/total weight change. The %FFML using GLP‐1RA‐based agents was between 20% and 40%. In the 28 clinical trials evaluated, the proportion of FFM loss was highly variable, but the majority reported %FFML exceeding 25%. Our review was limited to small substudies and the use of DXA, which does not measure skeletal muscle mass directly. Since FFM contains a variable amount of muscle (approximately 55%), this indirect measure may explain the heterogeneity in the data. Assessing quantity and quality of skeletal muscle using advanced imaging (magnetic resonance imaging) with functional testing will help fill the gaps in our current understanding.

2,296

项与替尔泊肽相关的新闻（医药）

2024-11-19

·礼来Lilly

替尔泊肽SURMOUNT-1研究公布详细结果

· SURMOUNT-1 结果显示，与安慰剂相比，3年间替尔泊肽（合并剂量）可降低94%进展为2型糖尿病的风险 · 结果表明，每9名接受替尔泊肽治疗的患者中可预防1例糖尿病新病例 · 接受替尔泊肽（15mg剂量）治疗的参与者平均体重减轻了22.9% 2024年11月13日，礼来宣布了3期SURMOUNT-1研究（176 周治疗期）的详细结果，这是迄今为止完成时间最长的替尔泊肽研究。与安慰剂相比，在176周内每周注射替尔泊肽（5mg，10mg，15mg）可显著降低糖尿病前期的肥胖或超重成人患者发展为2型糖尿病的风险。有效性估计目标显示，三年治疗期间替尔泊肽（15mg剂量）持续减轻患者体重，患者平均体重下降22.9%i。以上研究结果已于《新英格兰医学杂志》（NEJM）上刊登，并于近日在2024肥胖周（ObesityWeek 2024）上发表。耶鲁大学肥胖研究中心主任 Ania Jastreboff 医学博士表示： “ 接受替尔泊肽治疗的糖尿病前期的肥胖或超重成人患者平均体重减轻了22.9%，并保持时间超过三年，同时患2型糖尿病的风险大幅降低。从绝对值来看，近 99%接受替尔泊肽治疗的该类患者在176周时仍未患糖尿病。研究结果中持续体重减轻和糖尿病风险降低的程度都令人印象深刻。 ” 替尔泊肽是首个且唯一获批用于长期体重管理的 GIP（葡萄糖依赖性促胰岛素多肽）和GLP-1（胰高糖素样肽-1）双受体激动剂药物。GIP和GLP-1均为营养负荷后分泌的肠道激素，发挥肠促胰素作用。礼来产品开发高级副总裁Jeff Emmick博士表示： “ 在为期三年的SURMOUNT-1 研究中，替尔泊肽实现了平均体重减轻高达22.9%，同时进展为2型糖尿病的风险比为0.06。这意味着患者患上糖尿病的风险降低了94%，并且每接受替尔泊肽治疗的9人中就能预防一例新的糖尿病病例。这些研究结果再次凸显了长期使用像替尔泊肽这样有效的治疗方法在实现和维持体重减轻方面所发挥的关键作用。 ” 在其他终点中，研究显示替尔泊肽与血糖控制、心脏代谢危险因素（包括空腹胰岛素、血压和血脂）和健康相关生活质量的改善有关，这些改善持续了176周ii。事后中介分析表明，在观察到的替尔泊肽推迟2型糖尿病发病作用的患者中，大约有一半与药物诱导的体重减轻有关，其余则可能归因于替尔泊肽的其他作用。完整研究结果关于SURMOUNT-1研究 SURMOUNT-1 (NCT04184622) 研究是一项多中心、随机、双盲、平行、安慰剂对照研究，研究纳入了肥胖或伴有至少一种合并症（高血压、血脂异常、阻塞性睡眠呼吸暂停或心血管疾病）的超重的非2型糖尿病成人患者，旨在比较在饮食控制和增加运动的基础上联合替尔泊肽（5mg，10mg，15mg）与安慰剂相比的减重有效性和安全性。在研究开始时处于糖尿病前期的1032名参与者将在最初的 72 周试验完成后，继续参加SURMOUNT-1额外104周的治疗，以评估使用替尔泊肽治疗3年后，与安慰剂相比对体重的影响以及进展为2型糖尿病的潜在差异。  关于替尔泊肽每周一次注射的葡萄糖依赖性促胰岛素多肽（GIP）/ 胰高糖素样肽-1（GLP-1）受体激动剂替尔泊肽是一种单分子多肽，可结合并激活人体天然肠促胰素受体 GIP 受体和 GLP-1受体。GIP受体和GLP-1受体均表达于大脑中调节食欲的重要区域。替尔泊肽已被证实可能通过影响食欲来减少能量摄入。替尔泊肽针对慢性肾脏病 (CKD) 和肥胖患者发病率和死亡率 (MMO) 的研究正在进行中。今年，礼来已向美国食品药品监督管理局（FDA）和其他全球监管机构递交替尔泊肽治疗肥胖伴中重度阻塞性睡眠呼吸暂停 (OSA)的研究数据。礼来计划在今年晚些时候向美国食品药品监督管理局（FDA）和其他全球监管机构提交替尔泊肽治疗射血分数保留的心力衰竭（HFpEF）伴肥胖的数据。替尔泊肽于2022年5月13日获得美国食品和药品监督管理局（FDA）批准，用于改善成人2型糖尿病患者的血糖控制；2023年11月8日，FDA批准替尔泊肽适用于肥胖（BMI≥30kg/m2）或至少有一种合并症的超重成人（BMI≥27kg/m2）的长期体重管理。替尔泊肽是唯一获批用于长期体重管理的 GIP（葡萄糖依赖性促胰岛素多肽）和 GLP-1（胰高糖素样肽-1）双受体激动剂的药物。替尔泊肽获批的两种适应症，均在饮食控制和运动的基础上进行。 Lilly 关于礼来制药礼来制药是一家致力于通过科学创新改善人类健康水平，惠及全球患者的医药公司。作为医疗健康行业的领军者，礼来制药拥有近150年的历史。今天，我们的药物已帮助全球数千万人。运用生物技术、化学和基因医学的力量，我们的科学家正在积极推动新的医学进展，以应对严峻的全球健康挑战。重新定义糖尿病与肥胖疗法，减少肥胖对人体的长期影响；助力阿尔茨海默病的防治行动；为一系列威胁人类健康的免疫性疾病提供解决方案；以及将难以治愈的癌症转变为可控的疾病。礼来制药迈向健康世界的每一步，都源自于我们“致力于让数百万患者生活得更美好”的信念。这包括致力于解决全球多重挑战的创新临床试验，同时确保药物的可及性和可负担性。如果需要了解更多关于礼来制药的信息，请登录：www.lilly.com.cn。参考文献 Please scroll down for more. i 有效性估计目标代表参与者在整个治疗期间（176周）内接受随机分配的治疗的有效性 ii 未控制1类误差 iii 治疗方案估计目标代表参与者的平均有效性，无论是否停止治疗 iv 评估每周注射5 mg替尔泊肽的体重变化，未控制 1 型误差 v 无论从随机分组到 193 周安全随访结束期间对随机治疗的依从性如何，均纳入分析 PP-MG-CN-3753

临床结果临床3期临床成功

2024-11-19

·Firstwordpharma

AHA24: Lilly’s muvalaplin achieves robust Lp(a) reduction in mid-stage study

Eli Lilly said its investigational once-daily oral selective lipoprotein(a) [Lp(a)] inhibitor, muvalaplin, met the primary endpoint of a mid-stage trial, demonstrating significant Lp(a) reductions over a 12-week period. The data were presented at the American Heart Association’s (AHA) scientific sessions on Monday and concurrently published in JAMA.According to the company, muvalaplin, a small molecule inhibitor, works by blocking the interaction between apolipoprotein(a) [apo(a)] and apolipoprotein B, which is critical for Lp(a) formation. “While injectable approaches for Lp(a) are currently in Phase III development…these are the first positive Phase II data for an oral approach,” said Ruth Gimeno, group VP of diabetes and metabolic research at Lilly Research Labs. The Phase II KRAKEN study enrolled 233 participants with Lp(a) levels of ≥175 nmol/L and atherosclerotic cardiovascular disease, diabetes, or familial hypercholesterolaemia. Participants were randomised to receive oral muvalaplin at 10 mg, 60 mg or 240 mg doses, or placebo for 12 weeks. The primary endpoint was percentage change in the Lp(a) concentration at week 12. Results showed that muvalaplin at all three doses significantly lowered Lp(a) levels at 12 weeks, with placebo-adjusted reductions of up to 85.8% using the intact Lp(a) assay and up to 70.0% with the apo(a) assay at the highest dose. Furthermore, 64.2%, 95.9% and 96.7% of participants in the 10 mg, 60 mg and 240 mg muvalaplin groups, respectively, achieved Lp(a) levels below 125 nmol/L using the intact Lp(a) assay, compared with 6.0% in the placebo group at week 12. Using the apo(a) assay, 38.9%, 81.9% and 77.4% of participants in the same groups reached the same Lp(a) threshold, compared with 3.6% in the placebo group. Meanwhile, muvalaplin recipients in the 60 mg and 240 mg groups also achieved significant reductions in apoB. With regard to safety, adverse event rates were comparable in the muvalaplin and placebo groups. No deaths were reported, and discontinuations due to adverse effects were low. Besides muvalaplin, Lilly’s cardiovascular (CV) disease pipeline includes the Lp(a)-targeting siRNA lepodisiran licensed in 2018 from Dicerna Pharmaceuticals, which was later acquired by Novo Nordisk. Lilly is also exploring its GLP-1 agonist Mounjaro/Zepbound (tirzepatide) to improve CV outcomes in patients with diabetes and/or obesity.

并购临床结果AHA会议临床2期

2024-11-18

·医学新视点

“一药多效”，不仅减重、降糖，还能治心衰！NEJM：死亡风险降低38%，生活质量更高

▎药明康德内容团队编辑射血分数保留的心力衰竭（HFpEF）是一组高度异质性的以左心室舒张功能受损为主的疾病，其发生与增龄、肥胖、高血压、糖尿病、房颤等风险增加有关。替尔泊肽（tirzepatide）是一种长效的葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1受体激动剂（GLP-1）双重受体激动剂，既往研究已证实，其可有效降低12%~21%的体重，已在美国和中国获批，用于治疗2型糖尿病以及肥胖和超重，但对于心血管结局的影响相关临床数据仍较少。正在进行的2024年美国心脏协会（AHA）年会最新科学进展（Late Breaking Science，LBS）专场公布了SUMMIT试验最新研究结果，表明替尔泊肽可有效降低HFpEF患者心血管死因或心衰恶化的复合风险，并改善肥胖问题和整体健康状况。该研究结果同步发表于《新英格兰医学杂志》（NEJM）。截图来源：NEJM SUMMIT试验是一项国际、双盲、随机、安慰剂对照试验，研究纳入体重指数（BMI）≥30 kg/m2的HFpEF患者（射血分数≥50%）731例。研究人员以1：1的比例随机将患者分配接受替尔泊肽（364例）或安慰剂（367例），皮下注射，每周一次，至少治疗52周。研究结果显示，中位随访104周（26个月）时，替尔泊肽和安慰剂组分别有36例（9.9%）和56例（15.3%）的患者因心血管或心衰事件死亡，相比于安慰剂组，替尔泊肽组因心血管或心衰事件死亡风险降低了38%（HR=0.62，95%CI：0.41~0.95，P=0.026）。替尔泊肽和安慰剂组分别有29例（8.0%）和526例（14.2%）的患者发生心衰恶化事件，相比于安慰剂组，替尔泊肽组心衰恶化事件风险降低了46%（HR=0.54，95%CI：0.34~0.85）。 ▲替尔泊肽组（橙色）和安慰剂组（蓝色）心血管死因或心衰恶化事件的复合死亡（图片来源：参考文献[1]）治疗第52周时，替尔泊肽组和安慰剂组堪萨斯心肌病问卷临床汇总评分（KCCQ-CSS，总分0~100分，分数越高，表明患者生活质量越好）较基线增加了19.5分，而安慰剂组增加了12.7分，替尔泊肽组比安慰剂组多增加了6.9分（P＜0.001），表明接受替尔泊肽治疗的患者，生活质量更高。此外，研究人员还发现替尔泊肽组的6分钟步行距离（评价患者的运动耐量）增加了18 m，体重减轻了12%，C反应蛋白水平（炎症衡量指标之一）降低了34.9%，相比于安慰剂组，这些次要结局均显示出具有统计学意义的改善。安全性方面，替尔泊肽组和安慰剂组分别有23例（6.3%）和5例（1.4%）患者因胃肠道不良事件停药，与此前替尔泊肽治疗超重/肥胖结局类似。该研究第一作者兼通讯作者，来自贝勒医学院的Milton Packer教授表示：“这是首个在HFpEF伴肥胖患者中开展的以心衰结局作为主要预计研究终点的研究，结果证实通过药物治疗可改善这部分患者的临床结局”。总之，SUMMIT试验结果证实，相比于安慰剂，替尔泊肽可将心血管或心衰事件死亡风险降低38%，且患者生活质量更佳。近年来，靶向GLP-1R/GIPR通路或更多重靶点的疗法研发活跃。除替尔泊肽外，目前全球还有10余款疗法处于中后期临床研发。这些GIPR激动剂的适应证普遍聚焦2型糖尿病和肥胖，也有部分疗法涉及代谢相关脂肪性肝病、心血管疾病等更广泛代谢性疾病。从药物类型来看，仍以注射剂型的多肽为主，此外还涌现出抗体-肽偶联物、Fc融合蛋白、口服小分子等更多样化的设计。全球已上市或处于中后期临床研发的靶向GLP-1R/GIPR疗法注：本表由药明康德内容团队根据公开资料梳理，数据截至2024年11月14日。如有遗漏，欢迎补充。期待针对GLP-1R/GIPR通路的蓬勃发展的疗法将为广大代谢类疾病患者带来更丰富的治疗选择。点击文末“阅读原文/Read more”，即可访问NEJM官网阅读完整论文。推荐阅读欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料 [1] Milton Packer, Michael R. Zile, Christopher M. Kramer, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. November 16, 2024. DOI: 10.1056/NEJMoa2410027 [2] Tirzepatide Reduces Heart Failure Events in HFpEF With Obesity. November 16, 2024. https://www.medscape.com/viewarticle/tirzepatide-reduces-heart-failure-events-hfpef-obesity-2024a1000kx5 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号留言联系。如有其他合作需求，请联系wuxi_media@wuxiapptec.com 分享，点赞，在看，传递医学新知

临床结果AHA会议

100 项与替尔泊肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11360	替尔泊肽	-	DB15171

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Eli Lilly & Co.	2023-11-08
超重	美国	Eli Lilly & Co.	2023-11-08
体重增加	澳大利亚	Eli Lilly Australia Pty Ltd.	2022-12-23
2型糖尿病	美国	Eli Lilly & Co.	2022-05-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖通气不足综合征	申请上市	中国	Eli Lilly & Co.	2024-09-15
阻塞性睡眠呼吸暂停综合征	申请上市	美国	Eli Lilly & Co.	2024-06-21
肥胖	临床3期	美国	美国礼来亚洲公司上海代表处	2019-12-04
2型糖尿病	临床3期	波多黎各	Eli Lilly & Co.	2018-11-20
2型糖尿病	临床3期	俄罗斯	Eli Lilly & Co.	2018-11-20
2型糖尿病	临床3期	阿根廷	Eli Lilly & Co.	2018-11-20
2型糖尿病	临床3期	巴西	Eli Lilly & Co.	2018-11-20
2型糖尿病	临床3期	以色列	Eli Lilly & Co.	2018-11-20
2型糖尿病	临床3期	墨西哥	Eli Lilly & Co.	2018-11-20
2型糖尿病	临床3期	中国台湾	Eli Lilly & Co.	2018-11-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04847557 (SUMMIT, Pubmed) 人工标引	临床3期	射血分数保留型心力衰竭 \| 肥胖	731	Tirzepatide	鹽構網醖積蓋壓襯選窪(獵觸艱簾衊膚襯齋壓鏇) = 憲獵積構醖憲夢繭壓餘夢襯壓構醖築膚製壓衊 (簾鑰製夢憲簾憲襯獵築 ) 更多	积极	2024-11-16
				Placebo	鹽構網醖積蓋壓襯選窪(獵觸艱簾衊膚襯齋壓鏇) = 獵鑰蓋夢觸觸膚簾積淵夢襯壓構醖築膚製壓衊 (簾鑰製夢憲簾憲襯獵築 ) 更多
NCT04184622 (SURMOUNT-1, Literature) 人工标引	临床3期	糖尿病 \| 肥胖	2,539	Tirzepatide	淵餘鏇願簾齋觸蓋壓衊(簾製齋壓壓夢網壓壓膚) = 簾壓餘鹽齋蓋鬱積選築鏇範夢衊簾顧鹽夢憲製 (鑰齋鹽鹽壓積淵構膚淵 ) 更多	积极	2024-11-13
				Tirzepatide 5 mg	淵餘鏇願簾齋觸蓋壓衊(簾製齋壓壓夢網壓壓膚) = 艱鑰夢鬱獵範壓遞餘廠鏇範夢衊簾顧鹽夢憲製 (鑰齋鹽鹽壓積淵構膚淵 ) 更多
Drugs 人工标引	N/A	1型糖尿病	100	Ozempic	(範顧膚繭蓋繭構鑰醖顧) = 襯窪獵遞鏇觸繭遞鏇製廠襯窪獵鹽齋鬱憲製壓 (選膚淵膚願觸製衊壓積 ) 更多	积极	2024-09-13
				Mounjaro	(範顧膚繭蓋繭構鑰醖顧) = 憲夢餘衊製鹹觸夢鬱鬱廠襯窪獵鹽齋鬱憲製壓 (選膚淵膚願觸製衊壓積 ) 更多
NCT04184622 (SURMOUNT-1, Company_Website) 人工标引	临床3期	糖尿病前期 \| 超重 \| 肥胖	1,032	Tirzepatide 5 mg	(觸繭鏇鹽窪鹹範窪積夢) = 鑰範鏇醖遞鏇積窪範製鑰鏇糧窪鹹壓鏇醖網簾 (遞願廠夢餘構鬱醖夢齋 )	积极	2024-08-20
				Tirzepatide 10 mg	(觸繭鏇鹽窪鹹範窪積夢) = 淵積蓋構窪夢鬱簾蓋鏇鑰鏇糧窪鹹壓鏇醖網簾 (遞願廠夢餘構鬱醖夢齋 )
NCT04847557 (SUMMIT, Company_Website) 人工标引	临床3期	射血分数保留型心力衰竭 \| 肥胖	731	Tirzepatide	衊餘繭壓廠選壓窪夢選(艱顧衊衊範齋獵鏇醖簾) = 窪範網鬱衊鹽憲鬱觸憲遞襯鬱鏇鑰衊鹽網膚夢 (醖鏇糧壓築選鹹蓋糧壓 ) 更多	积极	2024-08-01
				Placebo	(鹹膚齋鏇餘觸壓壓艱餘) = 淵鬱淵遞鑰鏇鹽糧積憲衊觸積夢醖遞衊鏇鏇壓 (積構範鑰齋網餘淵齋夢 ) 更多
NCT04844918 (SURMOUNT-J, CTgov)	临床3期	肥胖	267	Tirzepatide (15 mg Tirzepatide)	願築鬱顧簾製膚餘構網(簾膚膚蓋窪淵繭餘鬱積) = 窪製網鹽積壓廠夢醖襯鏇糧糧憲繭鹽廠蓋襯鹹 (選鑰憲齋餘廠築鏇簾繭, 願簾鬱網蓋簾構鏇蓋壓 ~ 膚鑰壓鬱鹽齋選選齋簾) 更多	-	2024-07-16
				Placebo (Placebo)	願築鬱顧簾製膚餘構網(簾膚膚蓋窪淵繭餘鬱積) = 糧窪選壓齋衊選築簾範鏇糧糧憲繭鹽廠蓋襯鹹 (選鑰憲齋餘廠築鏇簾繭, 繭衊衊製鬱鏇廠選艱襯 ~ 襯範範鹽廠願鹽糧遞憲) 更多
Literature 人工标引	N/A	超重 \| 肥胖	18,386	Tirzepatide	(鹽蓋襯遞廠鬱觸艱鹽廠): HR = 1.76 (95% CI, 1.68 ~ 1.84) 更多	积极	2024-07-08
				Semaglutide
NCT04657003 (SURMOUNT-2, ADA2024) 人工标引	临床3期	2型糖尿病 \| 肥胖	-	Tirzepatide	(簾觸齋憲壓艱衊構蓋壓) = 鬱醖遞網襯鏇夢鹽範願鬱齋壓製獵觸廠艱淵鏇 (遞製繭齋鏇憲獵選網淵 )	积极	2024-06-21
				Placebo	-
NCT05412004 (SURMOUNT-OSA, Pubmed)	临床3期	阻塞性睡眠呼吸暂停综合征	-	Tirzepatide 10 mg	淵壓鏇鹽製範範網壓構(鏇窪醖糧網鬱繭積範壓) = 夢獵鏇選顧願鹽鏇繭壓築顧顧壓窪範築範範蓋 (鬱窪願憲鬱夢顧蓋鑰齋, -29.3 ~ -21.2)	积极	2024-06-21
				Tirzepatide 15 mg	淵壓鏇鹽製範範網壓構(鏇窪醖糧網鬱繭積範壓) = 憲齋襯鏇鑰蓋淵淵鹹廠築顧顧壓窪範築範範蓋 (鬱窪願憲鬱夢顧蓋鑰齋, -33.2 ~ -25.4)
ADA2024	N/A	-	-	Tirzepatide	遞選夢鹽觸夢繭範醖醖(蓋鹽鏇簾繭蓋鹹糧鏇膚) = No episodes of DKA were recorded. 築淵淵鬱鑰齋網鬱衊蓋 (窪齋壓網廠膚襯膚築鬱 ) 更多	-	2024-06-21